Gain’s initial data from its clinical study in parkinson’s patients presented at an event

Image Credit: Swisscore

Announcement 

Gain Therapeutics Inc., a leading clinical-level biotechnology company known for its development and exploratory-based next generation of allosteric small molecule therapies, has showcased the poster of parkinson’s disease and movement disorder at the international congress meeting emphasizing tolerability and safety presence, observation and primary endpoint form the major discoverable endpoint from its phase 1b clinical study of GT-02287 in individuals with parkinson’s disease (PD) without or with a GBA1 mutation.

Gain’s data poster

The poster title is ‘GT-02287 in parkinson’s disease: Interim data from a phase 1b study’. The poster was shown at a place by Jonas Hannestad, a chief medical officer, MD, Phd. It was seen that GT-02287 was tolerable with no treatment emergency negative drawback. A transient mitigation in different liver enzymes and alkaline phosphatase has been captured in a few participants, and normalization has even occurred with ongoing dosing. The data monitoring committee (DMC) in two different meetings has signalled consistency of the study.

Alongside, the Australian health authorities have also given a green signal to the phase 1b study expansion for patients who are qualified for 12 months of treatment. The poster in PDF format is available was spotted at the International Congress of parkinson’s disease and movement disorders. It’s also accessible under the science and technology section of Gain’s website at https://gaintherapeutics.com/science-and-technology/posters. 

The president and chief executive officer of Gain Therapeutics, Gene Mack, said, “We are glad to be able to showcase the empowering early takeaways from our phase 1b study. The popular improvement and balance we have noticed in MDS-UPDRS scores was surprising to witness over the 90 days of dosing. We’re heading towards explaining our observation in the coming webinar.”

Later, Gain Therapeutics will be hosting a webinar on 14^th October at 4:00 pm, to review the results shown at the International Congress of parkinson’s disease and Movement Disorders.

MDS-UPDRS improved scores

At baseline, the mean MDS-UPDRS score was 5.8, 7.4, and 24.7 for parts 1, 2, and 3. Numerous participants showed improvement, specifically in the 2 and 3 parts. The improvement in parts 2 and 3 by day 90 was surprising. It is advised that GT-02287 has the potential of the disease slowing effect based on the continued use of the preclinical models in vivo and the offered mechanism of action of GT-02287. This accelerates the ongoing development.